The AHSA1 Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population, generated through targeted disruption of the AHSA1 gene in Jurkat cells. This loss-of-function model enables investigation of AHSA1 (Activator of HSP90 ATPase Activity 1), a critical co-chaperone in the heat shock protein 90 (HSP90) chaperone cycle. The polyclonal knockout format provides a heterogeneous pool of edited cells, suitable for studying gene function without clonal selection artifacts. By eliminating AHSA1 expression, these cells serve as a versatile tool for dissecting the HSP90-dependent signaling networks that govern protein homeostasis, cellular stress responses, and T-cell biology.
The Jurkat host cell line is a human T lymphocyte model derived from an acute T-cell leukemia patient. These suspension cells exhibit robust T-cell receptor (TCR) signaling and are extensively employed in immunology, cancer biology, and signal transduction research. Jurkat cells recapitulate key aspects of T-cell activation, proliferation, and apoptosis, making them an ideal system for studying the roles of chaperone networks in immune cell function. Their leukemic origin also provides a relevant background for examining oncogenic signaling pathways that depend on molecular chaperones, particularly those involving HSP90 and its co-chaperones.
AHSA1 functions as a co-chaperone that directly stimulates the ATPase activity of HSP90, a master chaperone responsible for the maturation and stability of numerous client proteins. AHSA1 interacts with HSP90 isoforms (HSP90AA1, HSP90AB1) and cooperates with other co-chaperones, including HSP70, HOP, and p23 (PTGES3), to drive the ATP-dependent conformational cycle of HSP90. Upstream, AHSA1 expression is regulated by heat shock factor 1 (HSF1) and induced by cellular stresses such as heat shock and oxidative stress. Downstream, AHSA1-mediated activation of HSP90 facilitates the folding and activation of client proteins, including kinases (e.g., AKT, CDK4) and steroid hormone receptors, thereby directly linking stress responses to signal transduction and cell survival pathways.
In Jurkat T cells, the HSP90 chaperone machinery is essential for maintaining the stability of critical signaling kinases and transcription factors that propagate TCR-mediated signals and sustain leukemic cell growth. Knockout of AHSA1 disrupts HSP90’s ATPase cycle, impairing its chaperone function and leading to the degradation of HSP90-dependent client proteins. This results in attenuated T-cell signaling, reduced proliferation, and increased susceptibility to apoptosis. Given the frequent upregulation of HSP90 in T-cell malignancies, this knockout model offers a physiologically relevant system to decipher how AHSA1 contributes to leukemogenesis and to assess the dependency of leukemic T cells on functional HSP90 networks.
Researchers can utilize AHSA1 Knockout Jurkat Polyclonal Cells to investigate the mechanistic details of the HSP90 chaperone cycle, to map interactomes via co-immunoprecipitation of HSP90 complexes, and to evaluate the impact of chaperone disruption on T-cell signaling and survival. These cells are instrumental for drug discovery studies assessing sensitivity to HSP90 inhibitors such as geldanamycin and 17-AAG, with readouts including flow cytometric analysis of apoptosis and Western blot quantification of client proteins like AKT and CDK4. Additional applications encompass ATPase activity assays and RT-qPCR profiling of stress-response gene expression. For technical inquiries and ordering information, please contact Ascent Research.
